NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE117847 Query DataSets for GSE117847
Status Public on Jul 17, 2019
Title A retained transcriptomic profile characterizes the CD138+ cells in the progression from smoldering to active multiple myeloma
Organism Homo sapiens
Experiment type Expression profiling by array
Summary Smoldering myeloma (SMM) is a pre-malignant monoclonal gammopathy with a 10% annual risk to progress to active multiple myeloma (MM). SMM diagnostic criteria, as well of those of others monoclonal gammopathies, have been updated by the International Myeloma Working Group (IMWG) in 2014. In particular, the previously defined “ultra high-risk” SMM (characterized by the presence of specific biomarkers associated with a ≥ 80% risk of progression to symptomatic MM within 2 years) has been included among patients with active MM. SMM is biologically heterogeneous, including a subset of patients with biological pre-malignancy and a subset with biological malignancy who have not yet developed organ damage, defined as onset of the classical CRAB criteria or Myeloma Defining Events (MDE). Thus, SMM encompassed patients with a very low rate of progression to symptomatic MM, similar to patients with monoclonal gammopathy of uncertain significance (MGUS), as well as patients who acquired organ damage and progress to active MM within the first year from diagnosis. The molecular mechanisms involved in the SMM to MM progression are still far to be fully understood. Genomic studies indicate that the genetic alterations that characterize MM patients are already present in SMM ones, who present similar mutational and copy number alteration load. However, few data are available on the transcriptional profiles of SMM patients in relationship to the progression to active MM, overall indicating minimal differential expression either in coding or non-coding RNA fraction. To date, robust data are still lacking which describe the transcriptional profiles of plasma cells (PCs) from paired samples obtained at the time of SMM and at MM onset. Herein, we compared the transcriptome of purified CD138+ PCs from paired samples of SMM patients progressed to active MM (P-SMM), aimed at describing any possible common transcriptional discrepancy that may help to understand the intra-patient disease evolution; at the same time, we investigated the transcriptional differences between P-SMM and a subset of non-progressed SMM (NP-SMM) at a minimum of 36 months.
 
Overall design A total number of 20 SMM patients, admitted to the Hematological Unit of our Institution over the last 11 years, were considered: 12 non-progressed(NP)-SMM and 8 progressed(P)-SMM for whom paired active MM samples were available
 
Contributor(s) Storti P, Agnelli L, Della Palma B, Todoerti K, Marchica V, Accardi F, Deluca F, Bolzoni M, Craviotto L, Aversa F, Neri A, Giuliani N
Citation(s) 30846495, 32218309
Submission date Jul 30, 2018
Last update date May 26, 2020
Contact name Luca Agnelli
E-mail(s) luca.agnelli@istitutotumori.mi.it, luca.agnelli@gmail.com
Phone +390223903581
Organization name IRCCS Istituto Nazionale dei Tumori
Department Department of Advanced Diagnostics
Street address Venezian 1
City MILAN
ZIP/Postal code 20133
Country Italy
 
Platforms (1)
GPL25401 [Clariom_D_Human] Affymetrix Human Clariom D Assay [CDF: Brainarray ClariomDHuman_Hs_GENECODEG_22.0.0]
Samples (32)
GSM3310598 SMM at diagnosis, non-progressed sample 1
GSM3310599 SMM at diagnosis, sample 10
GSM3310600 SMM at diagnosis, non-progressed sample 2
Relations
BioProject PRJNA483417

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE117847_RAW.tar 834.9 Mb (http)(custom) TAR (of CEL)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap